Tumor treating fields (TTFields), a biophysical therapy technology that uses alternating electric fields to inhibit tumor proliferation, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of newly diagnosed or recurrent glioblastomas (GBM) and malignant pleural mesotheliomas (MPM). Clinical trials have confirmed that TTFields are effective in slowing the tumor growth and prolonging patient survival. In recent years, many researchers have found that TTFields can induce anti-tumor immune responses, and their main mechanisms include upregulating the infiltration ratio and function of immune cells, inducing the immunogenic cell death of tumor cells, modulating immune-related signaling pathways, and upregulating the expression of immune checkpoints. Treatment regimens combining TTFields with tumor immunotherapy are emerging as a promising therapeutic approach in clinical practice. Given the increasing number of recently published studies on this topic, we provide an updated review of the mechanisms and clinical implications of TTFields in inducing anti-tumor immune responses. This review not only has important reference value for an in-depth study of the anticancer mechanism of TTFields but also provides insights into the future clinical application of TTFields.
肿瘤治疗电场（TTFields）是一种利用交变电场抑制肿瘤增殖的生物物理疗法，已获美国食品药品监督管理局（FDA）批准用于治疗新诊断或复发性胶质母细胞瘤（GBM）及恶性胸膜间皮瘤（MPM）。临床试验证实，TTFields能有效延缓肿瘤生长并延长患者生存期。近年来多项研究发现，TTFields可诱导抗肿瘤免疫应答，其主要机制包括上调免疫细胞浸润比例与功能、诱导肿瘤细胞发生免疫原性死亡、调控免疫相关信号通路以及上调免疫检查点表达等。TTFields联合肿瘤免疫治疗在临床实践中逐渐成为具有潜力的治疗策略。基于近期该领域研究成果不断涌现，本文对TTFields诱导抗肿瘤免疫应答的作用机制及临床意义进行系统性综述，不仅对深入探究TTFields的抗癌机制具有重要参考价值，也为TTFields的未来临床应用提供新视角。
Research Progress on the Mechanism of Anti-Tumor Immune Response Induced by TTFields
肿瘤(癌症)患者之家